Murray M. Rosenberg Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York
Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care and Sleep Medicine
Director, Asthma Program
National Jewish Health
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California
Asthma Program Director
Division of Pulmonary & Critical Care Medicine
University of Michigan Pulmonary & Critical Care Medicine
Ann Arbor, Michigan
The educational design of this activity addresses the needs of pulmonologists, clinical immunologists/allergists, and other specialist clinicians who manage patients with severe asthma.
This enduring Call-a-Colleague™ educational program will guide attendees through the long-term management of severe asthma. Expert faculty will provide actionable recommendations on evaluation strategies that consider underlying mechanism of disease, data on newer biologic treatment options, and most importantly, the use of these therapies in current day practice. Interspersed throughout the program are brief Call-a-Colleague™ video calls in which faculty consult with their specialist colleagues to inform management decisions and gain additional insights into health disparities in asthma care and access, comorbid disease, initiation of biologics early within the disease course, and finally, treatment selection for challenging clinical cases.
After completing this activity, the participant should be better able to:
- Describe key pathophysiologic processes in severe asthma development and persistence, including the roles of TSLP and implications for treatment
- Discuss the clinical profiles and recent trial results with newer biologic therapies for severe asthma
- Construct biologic-based treatment regimens for patients with severe asthma to maximize asthma control, prevent exacerbations, and incorporate shared clinical decision making
Physician Accreditation Statement
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Chiesi USA, Inc., Kinaset Therapeutics, Genentech, Inc., GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Synairgen; Contracted Research: AstraZeneca plc, Janssen Pharmaceuticals, Sanofi S.A., Synairgen; Honoraria: Chiesi USA, Inc., Regeneron Pharmaceuticals, Inc.
Michael E. Wechsler, MD, MMSc: Consulting Fee: Amgen, Inc., Areteia Therapeutics, Inc., AstraZeneca plc, Avalo Therapeutics, Inc., Boehringer Ingelheim, Celldex Therapeutics, Inc., Cerecor Inc, Cohero Health, CytoReason, Eli Lilly and Company, Equillium, GSK plc, Incyte, Kinaset Therapeutics, Merck & Co., Novartis Pharmaceuticals Corporation, OM Pharma SA, Foresite Labs, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., resTORbio, Genentech, Inc., Sanofi S.A., Sentien Biotechnologies, Inc., Sound Biologics, Tetherex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Upstream Bio
Jonathan Corren, MD: Consulting Fee: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: Amgen, Inc., AstraZeneca plc, Novartis Pharmaceuticals Corporation, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Speakers Bureau: Amgen, Inc., AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Sanofi S.A.
Njira Lucia Lugogo, MD, MS: Consulting Fee: Amgen, Inc., AstraZeneca plc, Avillion LLP, Genentech, Inc., GSK plc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Contracted Research: Institution received research support from Amgen, Inc., AstraZeneca plc, Avillion LLP, Evidera, Gossamer Bio, Genentech, Inc., GSK plc, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Honoraria: AstraZeneca plc, GSK plc
The planners and managers at Integritas Communications have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Integritas Contact Information
For questions about this activity, please contact Integritas Communications at firstname.lastname@example.org.